Autopsy report · NCT00362466

A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy

“Insufficient Enrollment”

The sponsor’s own words in the registry.

Life of this trial

• Registered 8 months before it started.
• Ran for about 1 year 2 months before it stopped.
• 3 participants enrolled.
• Results were posted on the registry 1 year 3 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Bristol-Myers Squibb

Sponsor type

Industry

Conditions

Leukemia

Interventions

Dasatinib; Imatinib

Participants

3

Sites

45

Countries

United States

Trials that died the same way

• Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma
  “Insufficient enrollment rate” (91% match in meaning)
• Treatment Prior to Injection and Biopsy of the Vulva
  “Not enough enrollment” (91% match in meaning)
• Family Nurture Intervention in the CHoNJ NICU
  “insufficient enrollment numbers” (91% match in meaning)
• Development of Auditory Skills in Young Deaf Children With Bilateral Cochlear Implants
  “Not sufficient enrollment” (89% match in meaning)
• Outpatient Ultrafiltration Therapy in Heart Failure Patients Trial
  “Lack of enrollment” (89% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.